About this episode
In the November 5, 2024 issue of JACC, Dr. Valentin Fuster summarizes the November 5, 2024 issue of the JACC, which focuses exclusively on hypertrophic cardiomyopathy (HCM). Highlighting six original research papers, the discussion emphasizes the groundbreaking impact of the cardiac myosin inhibitor Aficamten on health outcomes, symptom burden, and cardiac structure in patients with obstructive HCM, while also exploring genetic screening implications for affected families.
Get every episode summarized
Each time JACC This Week publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from JACC This Week
March 10, 2026: Inside JACC Stats: The State of CV Health in Focus | JACC this W...
JACC This Week
March 3, 2026: Hypertrophic Cardiomyopathy in Focus—MAPLE-HCM Trial, Myosin Inh...
JACC This Week
February 24, 2026: ACHD Guideline in Focus—From Survival to Stewardship | JACC T...
JACC This Week
February 17, 2026: Women's Cardiovascular Health in Focus: From Inclusion to Red...
JACC This Week